News

I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and…
Read More...

Xeris Pharmaceuticals announced that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) for GVOKE (glucagon) injection, its ready-to-use,…
Read More...

IRBM announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic…
Read More...

The Netherlands-based biotech Citryll and CDMO Lonza announced a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013. CIT-013 targets Neutrophil…
Read More...

Thermo Fisher Scientific announced an agreement with Eli Lilly and Company for development of a companion diagnostic that will use the U.S Food and Drug Administration-approved,…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive results from two pivotal Phase 3 clinical studies (ASPIRE I & II) to evaluate the efficacy and…
Read More...

Horizon Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for teprotumumab, an investigational medicine…
Read More...

Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop…
Read More...

Genmab A/S announced today that it has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the…
Read More...

CMAB Biopharma (Suzhou) Inc. ("CMAB"), a pure-play contract development and manufacturing organization (CDMO) specializing in the production of mammalian cell-derived biologic products,…
Read More...

Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the Food and Drug Administration has recently granted mAb114, an experimental treatment for Ebola,…
Read More...

Roche announced that the European Commission has approved and granted marketing authorisation for Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide)…
Read More...

The U.S. Food and Drug Administration approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with…
Read More...

Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts. Schrödinger’s computational…
Read More...

A novel gene therapy treatment for rare inherited eye disorder has been recommended by NICE for use on the NHS. The draft highly specialized technologies guidance recommends…
Read More...

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted…
Read More...

JSR Life Sciences Companies Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome…
Read More...

Accelerated Enrollment Solutions (AES), a business unit of Pharmaceutical Product Development, LLC (PPD), has acquired the clinical research site business of Bioclinica, expanding AES’…
Read More...

American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announced an…
Read More...

AstraZeneca announced that it has received marketing authorisation from China’s National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for…
Read More...